Sources | Names Used |
---|---|
CTRPv2 | navitoclax:gemcitabine (1:1 mol/mol) |
PharmacoGx | navitoclax:gemcitabine (1:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | UPF3B | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
mRNA | TMED9 | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-06 |
mRNA | NABP1 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-06 |
mRNA | RP11-426L16.10 | CTRPv2 | pan-cancer | AAC | -0.2 | 1e-06 |
mRNA | RP11-106M3.2 | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-06 |
mRNA | PAFAH1B3 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
mRNA | KHSRP | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
mRNA | CHAF1B | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
mRNA | LIG1 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
mRNA | HNRNPDL | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |